Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate * At least 2 of the 3 following high-risk prognostic factors: * Gleason score of \>= 8 * Presence of 3 or more lesions on bone scan * Presence of measurable visceral (excluding lymph node disease) metastasis on computed tomography (CT) or magnetic resonance imaging (MRI) (Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1) * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * Hemoglobin \>= 9.0 g/dL independent of transfusion and/or growth factors within 3 months prior to enrollment * Platelet count \>= 100,000/uL independent of transfusion and/or growth factors within 3 months prior to enrollment * Serum albumin \>= 3.0 g/dL * Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Calculated creatinine clearance (Cockcroft-Gault equation) \>= 45 mL/min * Serum potassium \>= 3.5 mEg/L * Serum magnesium \>= 1.6 mg/dL * Serum bilirubin \< 1.5 x institutional upper limit of normal (IULN) (except for patients with known Gilbert's disease if total bilirubin is \> 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =\< 1.5 x ULN, subject may be eligible) * Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 2.5 x IULN for patients without liver metastases. (Note: In subjects with Gilbert…